NephroDI
Seattle, US · Delaware corporation · 1 known investors
Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI). Its work centers on renal physiology research and translating it toward clinical products.
Founders & leadership
JM
Jeff M. Sands, M.D.Co-founder
JS
Jeff Sands
JK
Janet Klein
JM
Jeff M. SandsChief Medical Officer & Founder
JD
Janet D. KleinDirector of Biology & Founder
RH
Rachael HaganPresident & Chief Executive Officer
FC
Fred CalloriNamed on SEC filing
DS
Donna SeeNamed on SEC filing
K
Khanna
P
Pillarisetti
Board
CG
Chris GarabedianBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.6M disclosed across 2 rounds · 2021–2024
▶$2MraisedJun 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJun 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rachael HaganExecutive Officer, Director
- Michael GrissingerDirector
- Bibhash MukhopadhyayDirector
- Jeff M. Sands, M.D.Executive Officer
- Offering amount
- $4M
- Amount sold
- $2M
- Proceeds to insiders
- $2.1M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedFeb 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedFeb 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Fred CalloriDirector
- Chris GarabedianDirector
- Donna SeeDirector
- Jeff M. Sands, M.D.Executive Officer
- Rachael HaganExecutive Officer, Director
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Nephrogen5 shared keywordsNephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.
Viridian Therapeutics5 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Novo Nordisk4 shared keywordsNovo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies. It serves patients and healthcare markets globally.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with NephroDI for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does NephroDI do?
- Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI). Its work centers on renal physiology research and translating it toward clinical products.
- Who founded NephroDI?
- NephroDI was founded by Jeff M. Sands, M.D., Jeff Sands, Janet Klein, Jeff M. Sands, Janet D. Klein.
- Who are NephroDI's investors?
- NephroDI's investors include Sound Bioventures.
- How much funding has NephroDI raised?
- NephroDI has disclosed $3.6M raised across 2 rounds.
- Where is NephroDI headquartered?
- NephroDI is headquartered in Seattle, US.